Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Acid-suppressing medications may be overprescribed for infants

21.10.2011
Commentary scrutinizes use of proton pump inhibitors for young children

Frequent spitting up, irritability and unexplained crying in infants are often very distressing to parents. Physicians frequently prescribe acid-suppressing drugs for these symptoms.

However, gastroesophageal reflux disease (GERD) is an uncommon cause of these symptoms in otherwise thriving infants, and in his commentary published in the Journal of Pediatrics, Dr. Eric Hassall cautions against over-diagnosis of GERD and over-prescription of acid-suppressing drugs in children under one year of age.

Dr. Hassall, a member of the division of gastroenterology at BC Children's Hospital, a professor of pediatrics at the University of British Columbia, and an advisor to the U.S. Food and Drug Administration, traces the history and current uses of acid-suppressing medication in children and infants, mostly focusing on proton pump inhibitors (PPIs). He points out that clinical studies have shown PPIs to be highly effective in children 1 to 17 years of age who have proven GERD.

In children under the age of one year, the use of these drugs has enormously increased in the last decade, a change in medical practice that Dr. Hassall says is not based in medical science. The rise of prescriptions owes a lot to direct-to-consumer advertising of pharmaceutical products, with its promotion of the misleading term "acid reflux," frequent self-misdiagnosis, and demand for medication. As Dr. Hassall observes, "it is recognized that more advertising leads to more requests by patients for advertised medicine, and more prescriptions; the term 'acid reflux' as used in the marketing of PPIs to adults, has simply trickled down to infants." He points out that most "reflux" in infants is not "acid," because stomach contents have been buffered by frequent feedings.

Randomized, controlled studies have shown that PPIs are no better than placebo for most infants with symptoms of spitting up and irritability, or unexplained crying. Dr Hassall explains that this is because the medications are frequently prescribed for symptoms that are not GERD. He emphasizes that spitting up in otherwise healthy, thriving infants is normal, and resolves with time; this is known as "physiological reflux." As infants have a limited range of responses to stimuli, it can be difficult to diagnose their cause. Irritability or unexplained crying, with or without spitting up, is often a normal developmental phenomenon especially in infants two to five months or so, less commonly thereafter. Some infants, once crying, are unable to self-calm. This improves with maturation and age. "The state of being new in the world and getting used to new bodily sensations, such as gassiness," also may contribute. When severe unexplained crying occurs in otherwise healthy infants, prevalent causes include sensitivity to cow's milk protein or other dietary components, including those that are present in breast milk. Nonpharmacological measures such as dietary changes, together with 'tincture of time' and reassurance, usually result in resolution.

As Dr. Hassall explains: "In the absence of better information and physician guidance and fed by advertising and misinformation on the Internet, parent blogs have increasingly promoted the ''my-baby-has-acid-reflux-and-needs-drugs'' concept. Parents, concerned by their infant's symptoms of apparent suffering, take their concern to doctors, who very frequently comply and prescribe acid-suppressing medications for symptoms and signs that in most cases are not GERD. GERD-mania is in full cry, so to speak."

"We are medicalizing normality," Dr. Hassall asserts, "In most infants, these symptoms are 'life,' not a disease, and do not warrant treatment with drugs, which can have significant adverse effects." He explains that gastric acid is an early line of defense against infection, and important for nutrition, and by prescribing acid suppressing medications, especially PPIs, to infants without GERD, pediatricians are putting their patients at a higher risk for infections like pneumonia and gastroenteritis. The use of PPIs in infants can also lead to abnormalities in the levels of essential minerals and vitamins, such as magnesium, calcium, and vitamin B12.

Dr. Hassall encourages his fellow pediatricians to opt initially for nonpharmacological approaches, such as changes in maternal diet of breastfeeding mothers, or hypoallergenic formulas for bottle-feeding infants. However, if these fail, or if an infant has severe symptoms and is suspected of having GERD, Dr. Hassall suggests beginning treatment initially with an histamine-2-receptor antagonist (such as ranitidine or famotidine) for a time-limited period of 2-weeks. If the infant does show improvement, dosage and length of treatment can be increased if necessary, or a trial of once-daily PPI started. However, as Dr. Hassall notes, "In most cases, it is not the spitting up that should be treated. The real issue is the unexplained crying, which causes real and considerable distress and concern for parents." He goes on to explain, "Parents can hardly be blamed for becoming rattled and concerned about their crying infant. It is important to acknowledge their concerns, explain the spectrum of normal infant behavior, discuss the range of measures available, start implementation, and be available for follow-up."

Dr. Hassall is available for interview, however he is on leave from his position at BC Children's Hospital, and is currently at Sutter Pacific Medical Foundation in San Francisco, California.

Brian Kladko | EurekAlert!
Further information:
http://www.ubc.ca

More articles from Health and Medicine:

nachricht How cancer metastasis happens: Researchers reveal a key mechanism
19.01.2018 | Weill Cornell Medicine

nachricht Researchers identify new way to unmask melanoma cells to the immune system
17.01.2018 | Duke University Medical Center

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Artificial agent designs quantum experiments

On the way to an intelligent laboratory, physicists from Innsbruck and Vienna present an artificial agent that autonomously designs quantum experiments. In initial experiments, the system has independently (re)discovered experimental techniques that are nowadays standard in modern quantum optical laboratories. This shows how machines could play a more creative role in research in the future.

We carry smartphones in our pockets, the streets are dotted with semi-autonomous cars, but in the research laboratory experiments are still being designed by...

Im Focus: Scientists decipher key principle behind reaction of metalloenzymes

So-called pre-distorted states accelerate photochemical reactions too

What enables electrons to be transferred swiftly, for example during photosynthesis? An interdisciplinary team of researchers has worked out the details of how...

Im Focus: The first precise measurement of a single molecule's effective charge

For the first time, scientists have precisely measured the effective electrical charge of a single molecule in solution. This fundamental insight of an SNSF Professor could also pave the way for future medical diagnostics.

Electrical charge is one of the key properties that allows molecules to interact. Life itself depends on this phenomenon: many biological processes involve...

Im Focus: Paradigm shift in Paris: Encouraging an holistic view of laser machining

At the JEC World Composite Show in Paris in March 2018, the Fraunhofer Institute for Laser Technology ILT will be focusing on the latest trends and innovations in laser machining of composites. Among other things, researchers at the booth shared with the Aachen Center for Integrative Lightweight Production (AZL) will demonstrate how lasers can be used for joining, structuring, cutting and drilling composite materials.

No other industry has attracted as much public attention to composite materials as the automotive industry, which along with the aerospace industry is a driver...

Im Focus: Room-temperature multiferroic thin films and their properties

Scientists at Tokyo Institute of Technology (Tokyo Tech) and Tohoku University have developed high-quality GFO epitaxial films and systematically investigated their ferroelectric and ferromagnetic properties. They also demonstrated the room-temperature magnetocapacitance effects of these GFO thin films.

Multiferroic materials show magnetically driven ferroelectricity. They are attracting increasing attention because of their fascinating properties such as...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

10th International Symposium: “Advanced Battery Power – Kraftwerk Batterie” Münster, 10-11 April 2018

08.01.2018 | Event News

See, understand and experience the work of the future

11.12.2017 | Event News

Innovative strategies to tackle parasitic worms

08.12.2017 | Event News

 
Latest News

Let the good tubes roll

19.01.2018 | Materials Sciences

How cancer metastasis happens: Researchers reveal a key mechanism

19.01.2018 | Health and Medicine

Meteoritic stardust unlocks timing of supernova dust formation

19.01.2018 | Physics and Astronomy

VideoLinks
B2B-VideoLinks
More VideoLinks >>>